Cheng Isaac
Known title: DirectorCIK: 0001829696
Cheng Isaac's purchase track record
Cheng Isaac has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/6/2022 | AMLX | $125K | -21.4% | +21.8% | -16.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMLX | ▼ Sell | Other | 1,409,035 | — | 1/6/2022 | View on chart |
| AMLX | ▼ Sell | Other | 6,410,964 | — | 1/6/2022 | View on chart |
| AMLX | ▼ Sell | Other | 974,107 | — | 1/6/2022 | View on chart |
| AMLX | ▼ Sell | Other | 1,621,544 | — | 1/6/2022 | View on chart |
| AMLX | ▲ Buy | Open Market | 6,578 | $125K | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.